Objective: To study the correlation of IRAK1 and TRAF6 expression with inflammatory response and immune response in oral lichen planus lesions. Methods: Patients who were diagnosed with oral lichen planus in Ziyang Fi...Objective: To study the correlation of IRAK1 and TRAF6 expression with inflammatory response and immune response in oral lichen planus lesions. Methods: Patients who were diagnosed with oral lichen planus in Ziyang First People's Hospital between June 2014 and February 2017 were selected as the OLP group of the study, and the oral lichen planus lesions were collected;42 patients who accepted surgery for oral trauma or maxillofacial plastic surgery were selected as the control group of the study, and the normal oral mucosa tissue was collected. The expression of IRAK1, TRAF6 and TLR4 signaling pathway molecules, Th1/Th2/Treg/Th17 transcription factors and cytokines in tissue samples were detected. Results:IRAK1, TRAF6, TLR4, MyD88 and NF-kB mRNA expression and protein expression in oral lichen planus lesions of OLP patients were significantly lower than those of control group, T-bet and IFN-γ levels were significantly lower than those of control group, and GATA3, FOXP3, RORγt, IL-4, IL-10 and IL-17 levels were significantly higher than those of control group;IRAK1 and TRAF6 expression in oral mucosa tissue were positively correlated with TLR4, MyD88 and NF-kB expression as well as T-bet and IFN-γ levels, and were negatively correlated with GATA3, FOXP3, RORγt, IL-4, IL-10 and IL-17 levels. Conclusion: IRAK1 and TRAF6 expression in oral lichen planus lesions can inhibit the TLR4 inflammatory response pathway and lead to Th1/Th2 /Treg/Th17 immune response disorder.展开更多
<b><span style="font-family:Verdana;">Background:</span></b><span style="font-family:Verdana;"> Oral potentially malignant disorders, which include oral lichen planus ...<b><span style="font-family:Verdana;">Background:</span></b><span style="font-family:Verdana;"> Oral potentially malignant disorders, which include oral lichen planus (OLP), are clinical presentations that carry a risk of development to cancer in the oral cavity. Oral lichenoid lesions (OLLs) are also termed interface/lichenoid mucositis. Malignant transformation of them remains controversial, but distinct clinical and histological criteria for how to differentiate OLP from OLLs have not been developed.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> The purpose of this study was to elucidate findings that can allow histopathological differentiation of OLP and OLLs using histomorphological and immunohistochemical analyses.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Analyses were performed in 10 cases diagnosed with OLP and 9 cases diagnosed with OLLs. Cytokeratin 19 (CK19), Ki-67 and CD3 were used as primary antibodies to detect basal cells, proliferative activity and T-cell distribution, respectively</span><span style="font-family:Verdana;">, and</span><span style="font-family:Verdana;"> Perlecan and COX-2 to evaluate epithelial intracellular arrangements and interstitial distributions of proteoglycans and enzymes. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> For CK19, positive cells were significantly found in OLLs at both the prominent area and site adjacent to the lesion comparison with those of OLP’s. The number of COX-2 positive cells was significantly higher in spinous and basal layers in OLLs of the prominent area. Additionally, OLLs showed mild to moderate expression for perlecan in the basal to spinous layers and in subepithelial tissue. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Almost no basal cells were noted in the prominent area in OLP. COX-2 and perlecan were found in the basal to spinous layers in OLLs. Although there are restrictions, these suggested the possibility of helping to distinguish between OLP and OLLs.</span>展开更多
文摘Objective: To study the correlation of IRAK1 and TRAF6 expression with inflammatory response and immune response in oral lichen planus lesions. Methods: Patients who were diagnosed with oral lichen planus in Ziyang First People's Hospital between June 2014 and February 2017 were selected as the OLP group of the study, and the oral lichen planus lesions were collected;42 patients who accepted surgery for oral trauma or maxillofacial plastic surgery were selected as the control group of the study, and the normal oral mucosa tissue was collected. The expression of IRAK1, TRAF6 and TLR4 signaling pathway molecules, Th1/Th2/Treg/Th17 transcription factors and cytokines in tissue samples were detected. Results:IRAK1, TRAF6, TLR4, MyD88 and NF-kB mRNA expression and protein expression in oral lichen planus lesions of OLP patients were significantly lower than those of control group, T-bet and IFN-γ levels were significantly lower than those of control group, and GATA3, FOXP3, RORγt, IL-4, IL-10 and IL-17 levels were significantly higher than those of control group;IRAK1 and TRAF6 expression in oral mucosa tissue were positively correlated with TLR4, MyD88 and NF-kB expression as well as T-bet and IFN-γ levels, and were negatively correlated with GATA3, FOXP3, RORγt, IL-4, IL-10 and IL-17 levels. Conclusion: IRAK1 and TRAF6 expression in oral lichen planus lesions can inhibit the TLR4 inflammatory response pathway and lead to Th1/Th2 /Treg/Th17 immune response disorder.
文摘<b><span style="font-family:Verdana;">Background:</span></b><span style="font-family:Verdana;"> Oral potentially malignant disorders, which include oral lichen planus (OLP), are clinical presentations that carry a risk of development to cancer in the oral cavity. Oral lichenoid lesions (OLLs) are also termed interface/lichenoid mucositis. Malignant transformation of them remains controversial, but distinct clinical and histological criteria for how to differentiate OLP from OLLs have not been developed.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> The purpose of this study was to elucidate findings that can allow histopathological differentiation of OLP and OLLs using histomorphological and immunohistochemical analyses.</span><span style="font-family:Verdana;"> </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Analyses were performed in 10 cases diagnosed with OLP and 9 cases diagnosed with OLLs. Cytokeratin 19 (CK19), Ki-67 and CD3 were used as primary antibodies to detect basal cells, proliferative activity and T-cell distribution, respectively</span><span style="font-family:Verdana;">, and</span><span style="font-family:Verdana;"> Perlecan and COX-2 to evaluate epithelial intracellular arrangements and interstitial distributions of proteoglycans and enzymes. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> For CK19, positive cells were significantly found in OLLs at both the prominent area and site adjacent to the lesion comparison with those of OLP’s. The number of COX-2 positive cells was significantly higher in spinous and basal layers in OLLs of the prominent area. Additionally, OLLs showed mild to moderate expression for perlecan in the basal to spinous layers and in subepithelial tissue. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> Almost no basal cells were noted in the prominent area in OLP. COX-2 and perlecan were found in the basal to spinous layers in OLLs. Although there are restrictions, these suggested the possibility of helping to distinguish between OLP and OLLs.</span>